Literature DB >> 8943099

Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor.

T L Cascino1, M H Veeder, J C Buckner, J R O'Fallon, M Wiesenfeld, R Levitt, R M Goldberg, S A Kuross, R F Morton, B W Scheithauer.   

Abstract

Thirty patients with recurrent primary brain tumors were treated with a combination of 5-fluorouracil and leucovorin. There were three responses seen. Toxicity consisted of stomatitis, diarrhea, and hematological suppression. 5-fluorouracil and leucovorin would appear to be minimally effective in recurrent brain tumors.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8943099     DOI： 10.1007/bf00177275

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  5 in total

1.  Glioblastoma multiforme. An analysis of the results of postoperative radiotherapy alone versus radiotherapy and concomitant 5-fluorouracil. (A prospective randomized study of 32 cases).

Authors:  R W Edland; M Javid; F J Ansfield
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1971-02

2.  Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas.

Authors:  V A Levin; S Phuphanich; H C Liu; V Da Silva; J Murovic; A Choucair; M Chamberlain; M Berger; M Seager; R L Davis
Journal:  Cancer Treat Rep       Date:  1986-11

Review 3.  Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.

Authors:  M A Poon; M J O'Connell; C G Moertel; H S Wieand; S A Cullinan; L K Everson; J E Krook; J A Mailliard; J A Laurie; L K Tschetter
Journal:  J Clin Oncol       Date:  1989-10       Impact factor: 44.544

4.  A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma.

Authors:  W R Shapiro; S B Green; P C Burger; R G Selker; J C VanGilder; J T Robertson; J Mealey; J Ransohff; M S Mahaley
Journal:  J Neurosurg       Date:  1992-05       Impact factor: 5.115

5.  Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine.

Authors:  L A Rodriguez; M Prados; D Fulton; M S Edwards; P Silver; V Levin
Journal:  Neurosurgery       Date:  1988-04       Impact factor: 4.654
  5 in total
  5 in total

1.  A North Central Cancer Treatment Group phase II trial of topotecan in relapsed gliomas.

Authors:  P A Burch; A M Bernath; T L Cascino; B W Scheithauer; P Novotny; S Nair; J C Buckner; D M Pfeifle; J W Kugler; L K Tschetter
Journal:  Invest New Drugs       Date:  2000-08       Impact factor: 3.850

2.  Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome.

Authors:  Jessica M Grunda; John Fiveash; Cheryl A Palmer; Alan Cantor; Hassan M Fathallah-Shaykh; L Burt Nabors; Martin R Johnson
Journal:  Clin Cancer Res       Date:  2010-05-11       Impact factor: 12.531

3.  Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression.

Authors:  Omar D Perez; Christopher R Logg; Kei Hiraoka; Oscar Diago; Ryan Burnett; Akihito Inagaki; Dawn Jolson; Karin Amundson; Taylor Buckley; Dan Lohse; Amy Lin; Cindy Burrascano; Carlos Ibanez; Noriyuki Kasahara; Harry E Gruber; Douglas J Jolly
Journal:  Mol Ther       Date:  2012-05-01       Impact factor: 11.454

4.  The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.

Authors:  Karla V Ballman; Jan C Buckner; Paul D Brown; Caterina Giannini; Patrick J Flynn; Betsy R LaPlant; Kurt A Jaeckle
Journal:  Neuro Oncol       Date:  2006-11-15       Impact factor: 12.300

5.  Neural Stem Cell-Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients.

Authors:  Jana Portnow; Timothy W Synold; Behnam Badie; Revathiswari Tirughana; Simon F Lacey; Massimo D'Apuzzo; Marianne Z Metz; Joseph Najbauer; Victoria Bedell; Tien Vo; Margarita Gutova; Paul Frankel; Mike Chen; Karen S Aboody
Journal:  Clin Cancer Res       Date:  2016-12-15       Impact factor: 12.531
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.